DOC Dosage Guide

## Overdose Profile ### Extreme Duration as a Risk Factor DOC's most distinctive danger in overdose scenarios is its **extraordinarily long duration of action**. Effects can persist for **18--24 hours or longer** at high doses, meaning that adverse effects --- including cardiovascular strain, psychological distress, and autonomic instability --- can be sustained for an entire day or more without reprieve. This is in stark contrast to classical psychedelics like LSD (8--12 hours) or psilocybin (4--6 hours) [1]. The slow onset (up to 3 hours to reach full effects) creates a specific hazard: users may **redose prematurely** believing their initial dose was inactive, inadvertently consuming a dangerously large total amount. This pattern has been documented across the DOx compound class and is considered a primary contributor to adverse events [2]. ### Cardiovascular Strain As a substituted amphetamine, DOC produces sustained **sympathomimetic stimulation** including: - **Tachycardia and hypertension** persisting for the full duration of effects (potentially 24+ hours) - **Peripheral vasoconstriction** that can cause numbness, coldness, and discoloration of extremities - **Cardiac arrhythmia risk** from prolonged adrenergic stimulation ### DOx-Class Fatalities While no deaths have been conclusively attributed to DOC alone in the published literature, the broader **DOx compound class** has been associated with fatalities. DOB (the bromo analogue) and Bromo-DragonFLY (a structurally related compound) have caused documented deaths involving seizures, hyperthermia, and cardiovascular collapse [3]. DOC shares the same pharmacological mechanism (potent 5-HT2A agonism combined with amphetamine-like stimulation), so similar outcomes cannot be ruled out at high doses or in vulnerable individuals. ### Management Management of DOC overexposure is supportive: benzodiazepines for agitation and seizures, monitoring of cardiovascular parameters, and treatment of hyperthermia if present. The extended duration means that clinical observation should continue for **at least 24 hours**. ## References [1] Shulgin A, Shulgin A. PiHKAL: A Chemical Love Story. Transform Press; 1991. [2] EMCDDA. DOx compound class risk assessment summary. [3] Erowid. DOB vault: health and fatality reports. erowid.org.